- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
Setting: Hospital
Encompassing all units and departments within a hospital setting
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- Adults (18-64 years)
- Elderly (≥65 years)
- Healthcare workers
- Hospital
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Respiratory syncytial virus infection
- Influenza
- COVID-19
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Emergency department
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Respiratory syncytial virus infection
- Influenza
- COVID-19
- Fragile population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Palivizumab
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Emergency department
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Respiratory syncytial virus infection
- Influenza
- COVID-19
- General population
- Infants (<1 year)
- Hospital
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Respiratory syncytial virus infection
- Influenza
- COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab